Anti-Human IDUA Polyclonal Antibody

Catalog No.

PHE11401

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human IDUA (Ala28-Trp306).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

IDUA, Alpha-L-iduronidase

Purification

Purified by antigen affinity column.

Accession

P35475

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Antibodies to recombinant human alpha-L-iduronidase prevent disease correction in cortical bone in MPS I mice., PMID:40123743

α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial., PMID:38204164

Generation and Characterization of Iduronidase-Cleavable ADCs., PMID:38054705

Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice., PMID:37251981

Ocular Tolerability and Immune Response to Corneal Intrastromal AAV-IDUA Gene Therapy in New Zealand White Rabbits., PMID:32542182

Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model., PMID:32439268

Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I., PMID:32330426

Dermatan sulfate epimerase 1 expression and mislocalization may interfere with dermatan sulfate synthesis and breast cancer cell growth., PMID:31972438

Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease., PMID:31060789

Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys., PMID:31017018

Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial., PMID:29976218

Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I., PMID:29442294

RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system., PMID:29198892

Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein., PMID:28279069

Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates., PMID:26022732

Effects of enzyme replacement therapy started late in a murine model of mucopolysaccharidosis type I., PMID:25646802

α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice., PMID:25597593

Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I., PMID:25027660

Mesenchymal stem cells do not prevent antibody responses against human α-L-iduronidase when used to treat mucopolysaccharidosis type I., PMID:24642723

Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice., PMID:23562162

IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys., PMID:23249376

Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor., PMID:22822036

Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-L-iduronidase partially corrects visceral pathology in mucopolysaccharidosis type I mice., PMID:22472038

Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein., PMID:21667973

Evaluation of a general practice based hepatitis C virus screening intervention., PMID:19728405

A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery., PMID:19180267

Cholera toxin subunit B detection in microfluidic devices., PMID:18777170

Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product., PMID:18523448

Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome., PMID:18037941

Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier., PMID:17680664

Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation., PMID:17311010

Synthesis of enzymatically active human alpha-L-iduronidase in Arabidopsis cgl (complex glycan-deficient) seeds., PMID:17177794

Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy., PMID:17044753

Gene therapy of the brain in the dog model of Hurler's syndrome., PMID:16718701

Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig., PMID:16698321

Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice., PMID:16482204

Enzyme replacement therapy in mucopolysaccharidosis type I., PMID:15895714

Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector., PMID:15703491

Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3., PMID:2220820

Document Download

Anti-Human IDUA Polyclonal Antibody.pdf